Better treatment for brain cancer revealed by new molecular insights
Nearly a third of adults with the most common type of brain cancer develop recurrent, invasive tumors after being treated with a drug called bevacizumab. The molecular underpinnings behind these detrimental effects have now been deciphered. The findings reveal a new treatment strategy that could reduce tumor invasiveness and improve survival in these drug-resistant patients.
